The acquisition would expand Medtronic’s offerings in orthopedic surgery and complement the company’s existing presence in spine, neurosurgery, neuromodulation, advanced energy and surgical navigation. The total value of the transaction, net of Kanghui’s cash, is expected to be approximately $755 million.
More Articles on Orthopedic Devices:
Amedica Receives FDA Approval for Interbody Fusion Device
